Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes (NCT06614504)
A Randomized Controlled Trial of Reduced Nicotine Cigarettes and E-cigarettes Among Dual Users
๐ฉบ Plain-English Summary (8th-Grade Level)
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the US. Use of multiple tobacco products is becoming increasingly prevalent, with dual use of e-cigarettes and cigarettes representing the most common combination. Though e-cigarettes are not without risk, completely switching from cigarettes to e-cigarettes likely reduces risk for tobacco-related harm. However, many established dual users maintain long-term smoking and the majority who use e-cigarettes non-daily are at an even greater risk for prolonged smoking than exclusive cigarette smokers. The Food and Drug Administration Center for Tobacco Products (FDA CTP) has announced plans to implement a nicotine-limiting product standard, capping the nicotine in cigarettes at a minimally or non-addictive level. Randomized controlled trials (RCTs) demonstrate that adults who exclusively smoke cigarettes respond to very low nicotine content (VLNC) cigarettes with reductions in smoking, demand, and dependence. However, nicotine reduction RCTs to date have excluded people who regularly use e-cigarettes and therefore it remains unclear how a nicotine-limiting standard for cigarettes would affect smoking among dual users. Given the potential substitutability of e-cigarettes for cigarettes, reducing the nicotine in cigarettes could promote a transition to exclusive e-cigarette use among dual users unable to completely quit nicotine, but only if sufficiently appealing e-cigarettes remain available. E-cigarettes containing 5% nicotine-salt solution are currently most popular in the US, but policy makers have proposed restricting e-cigarettes to โค 2% nicotine to curb youth e-cigarette use, and several states have already set limits to reduce nicotine in e-cigarettes. Prior laboratory studies indicate that higher vs lower nicotine e-cigarettes serve as better substitutes for cigarettes among adult dual users. As such, a restriction on e-cigarette nicotine concentration could undermine the potential for e-cigarettes to substitute for cigarettes and diminish the benefits of a nicotine-limiting standard for cigarettes among dual users. This study is a 12-week double-blind 2 cigarette level (Normal Nicotine vs Very Low Nicotine) x 2 e-cigarette level (High Nicotine vs Low Nicotine) between-subjects factorial trial to investigate how a nicotine-limiting standard for cigarettes affects adult dual users and whether these effects are impacted by constraints on e-cigarette nicotine concentration. Outcome measures include cigarettes per day, cigarette dependence, and toxicant exposure. The research is highly relevant to FDA CTP domains of Addiction and Behavior because it will test whether reducing the nicotine content of cigarettes reduces smoking and dependence, and whether these effects are moderated by the availability of high vs low nicotine e-cigarettes.
Who can join: Review the eligibility criteria below.
Location: Brown University โ Providence, Rhode Island
Age range: 21 Years
๐งช Interventions in This Study
- Varying the nicotine content of cigarettes (OTHER)
- Varying the nicotine content of e-cigarettes (OTHER)
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (2 Sites)
- Brown University โ Providence, Rhode Island
- University of Vermont โ Burlington, Vermont
๐ Contact the Study Coordinator
Phone: (802) 656-1641
Email: emily.booth@med.uvm.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Tobacco Use Disorder
- Nicotine Replacement Therapy Prescribing and Lung Cancer Screening in Hospitalized Patients โ Charleston, South Carolina
- Abstinence Reinforcement Therapy for Veterans Who Smoke Tobacco and Are Experiencing Homelessness โ Durham, North Carolina
- 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder โ Birmingham, Alabama
- Smoking Cessation Behavioral Treatment Study โ Columbia, Missouri
- Beta-Adrenergic Modulation of Drug Cue Reactivity โ Tulsa, Oklahoma
- An fMRI Study of the Effects of Clavulanic Acid on Drug Addiction โ Columbia, Missouri
Explore by condition: All Tobacco Use Disorder clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.